乌鸦传媒

MRD-negativity rates improved across subgroups, supporting daratumumab-lenalidomide combination

Subcutaneous administration of the anti-CD38 antibody also made for easier dosing

Less-intense belantamab mafodotin schedule proved more tolerable in combination regimen

Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease

Study shows the various factors behind refusal of autologous stem cell transplantation

DETERMINATION asks if we are doing more than necessary for transplant-eligible patients

Eileen Boyle, MD, PhD, discusses research to identify determinants of deep response to dara-KRd

Gareth Morgan, MD, PhD describes the takeaways from the Myeloma XI Trial

Noopur Raje, MD, discusses the results of the MagnetisMM-1 trial

Saad Usmani, MD, discusses follow-up results from the phase III MAIA study

Ken Shain, MD, discusses the updated analysis of GRIFFIN